The FDA has issued five warning letters to companies for selling products containing CBD in ways that violate the Federal Food, Drug, and Cosmetic Act, reports Food Business News. The companies include Bee Delightful, G&L Wellness, LLC, New Leaf Pharmaceuticals, LLC, NextL3evel Services Group, LLC, and Wellness BioSciences RX. The FDA claims that they were illegally marketing unapproved CBD products, claiming that they treat medical conditions such as anxiety and depression, post-traumatic stress disorders, rheumatoid arthritis, and ocular degeneration or disorders.
“We remain focused on exploring potential pathways for CBD products to be lawfully marketed while also educating the public about these outstanding questions of CBD’s safety,” said Amy Abernethy, MD, PhD, principal deputy commissioner for the FDA. “Meanwhile, we will continue to monitor and take action, as needed, against companies that unlawfully market their products — prioritizing those that pose the greatest risk of harm to the public.”
Since the products mentioned in the letters have not gone through the FDA drug approval process, the FDA considers them unapproved new drugs
